DNA testing for hypertrophic cardiomyopathy: A cost-effectiveness model

European Heart Journal

Volumn 31, Issue 8, 2010, Pages 926-935

  Wordsworth, Sarah ^a   Leal, José ^a   Blair, Edward ^b,c   Legood, Rosa ^d   Thomson, Kate ^b   Seller, Anneke ^b   Taylor, Jenny ^e   Watkins, Hugh ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cost effectiveness analysis; Genetics; Hypertrophic cardiomyopathy

Indexed keywords

ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; GENETIC COUNSELING; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; GROUPS BY AGE; HEART FAILURE; HETEROZYGOTE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LIFESTYLE MODIFICATION; MOLECULAR GENETICS; MORTALITY; MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; STROKE; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CHILD; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DECISION TREES; FORECASTING; GENETIC TESTING; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; PEDIGREE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 77951112882     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq067     Document Type: Article

References (31)

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED, American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents; European Society of Cardiology Committee for Practice Guidelines. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-1991.
2. Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. Clinical, demographic, and pathological pro-files. J Am Med Assoc 1996;276:199-204.
3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363: 1881-1891.
4. Elliott PM, Gimeno JR, Thaman R, Shah J, Dickie S, Tome Esteban MT, McKenna WJ. Historical trends in reported survival rates in patients with hyper-trophic cardiomyopathy. Heart 2006;92:785-791.
5. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, Mahon NG, McKenna WJ. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-2218.
6. Ashrafian H, Watkins H. Cardiomyopathies: therapeutics based on molecular phenotype. J Am Coll Cardiol 2007;49:1251-1264.
7. Maron BJ. Hypertrophic Cardiomyopathy: a systematic review. J Am Med Assoc 2002;287:1308-1320.
8. Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, Graham KJ, Burton DA, Cecchi F. Epidemiology of hypertrophic cardiomyopathy-related death\revisited in a large non-referral-based patient population. Circulation 2000;102:858-864.
9. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: management, risk stratifi-cation, and prevention of sudden death. Heart 2002;87:169-176.
10. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol 2008;51:e1-e62
11. National Service Framework for Coronary Heart Disease. Chapter 8: Arrhythmias and Sudden Cardiac Death. Department of Health, 2005. http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/ Coronaryheartdisease/DH-4117048?Idc Service=GET-FILE&dID= 10043&Rendition=Web.
12. Office for National Statistics. Social Trends no36, 2006 ed. HMSO, 2006. http://www.statistics.gov.uk/downloads/theme-social/Social-Trends36/ Social-Trends- 36.pdf.
13. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC, Tu JV, Alter D A. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003;41:1573-1582.
14. Ezekowitz JA, Armstrong PW, McAlister F A. Implantable cardioverter defibrilla-tors in primary and secondary prevention: a systematic review of randomized, controlled trials. Ann Intern Med 2003;138:445-452.
15. Leal J, Wordsworth S, Legood R, Blair E. Eliciting expert opinion for economic models: an applied example. Value Health 2007;10:195-203.
16. Government Actuary's Department. Life tables 2002-4. http://www.gad.gov. uk/Demography-Data/Life-Tables/.
17. British Heart Foundation. Coronary Heart Disease Statistics, 2006 ed. British Heart Foundation, 2006. http://www.bhf.org.uk/plugins/DocSearch/ Download.aspx?sFile= 6cb9b419-5732-4e6e-b4ca-68c87208572d-1-0&sExt=.pdf.
18. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, on behalf of the Oxford Vascular Study. Population-based study of event rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories. Lancet 2005;366: 1773-1783.
19. Charron P, Dubourg O, Desnos M, Isnard R, Hagege A, Millaire A, Carrier L, Bonne G, Tesson F, Richard P, Bouhour JB, Schwartz K, Komajda M. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation 1997;96: 214-219.
20. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, Benaiche A, Isnard R, Dubourg O, Burban M, Gueffet JP, Millaire A, Desnos M, Schwartz K, Hainque B, Komajda M. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2171-2174.
21. Curtis L. Unit Costs of Health and Social Care. University of Kent, Personal Social Services Research Unit; 2007. http://www.pssru.ac.uk.
22. Department of Health. NHS reference costs 2006-2007. http://www.dh.gov. uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH-074072.
23. Petersen S, Rayner M, Wolstenholme J. Coronary Heart Disease Statistics: Heart Failure Supplement. London: BHF; 2002. http://www.heartstats.org/topic. asp?id=813.
24. Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determi-nants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 2006;37:2579-2587.
25. Parkes J, Bryant J, Milne R. Implantable cardioverter defibrillators: arrhythmias A rapid and systematic review. Health Technol Assess 2000;4: http://www.ncchta.org/fullmono/mon426.pdf.
26. Wilson BJ, Torrance N, Mollison J, Wordsworth S, Gray JR, Haites NE, Grant A, Campbell MK, Miedyzbrodzka Z, Clarke A, Watson MS, Douglas A. Improving the referral process for familial breast cancer genetic counselling: findings of three randomized controlled trials of two interventions. Health Technol Assess 2005;9: 1-146. http://www.ncchta.org/fullmono/mon903.pdf.
27. HM Treasury. Green Book, Appraisal and Evaluation in Central Government. http://greenbook.treasury.gov.uk/. 2004.
28. NICE. Social value judgments: principles for the development of NICE guidance. 8 December. 2005. http://www.nice.org.uk/media/873/2F/SocialValue JudgementsDec05.
29. Claxton K, Sculpher M, McCabe C, Briggs AH, Akehurst R, Buxton M, Brazier J, O'Hagan T. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339-347.
30. Briggs A, Sculpher M, Claxton K. Decision Modeling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
31. Hershberger R, Lindenfeld J, Mestroni L, Seidman C, Taylor M, Towbin J. Genetic evaluation of cardiomyopathy\a heart failure society of America practice guide-line. J Card Fail 2009;15:83-97.